Delivering medical care to a large number of patients

SanBio's Cell Therapy Medicine (MSC implantation) employs allogeneic transplantation. Compared to the laborious, time-consuming, and costly process of autologous transplantation, it is possible to produce large quantities of homogenous products at lower costs. SanBio aims to deliver medical care to as many patients as possible.

Large-scale production technology

To produce large quantities of homogenous products from living cells, knowledge and expertise about cells, as well as time and perseverance are required. SanBio invested roughly 10 years in becoming successful in scaling up its production of drugs made with living cells.

World-leading development team

We brought on board professor Hideyuki Okano, the leader of regenerative medicine and iPS cell research, as the founding scientist of our company. Shinya Hirata, and Keizo Nakada are in charge of the R&D and Production Department, respectively. Having the world's top-level development team is one of SanBio’s Strengths.